Abstract 2333P
Background
The aim of this study was to investigate the correlation of BRCA1 promoter methylation status (BRCA1met) in patients with triple-negative breast cancer (TNBC) to clinicopathological and molecular variables, patient prognosis, patient response to neoadjuvant chemotherapy (NAC), and potential therapy resistance mechanisms in NAC treated patients.
Methods
145 patients enrolled 2015-2018 in the Sweden Cancerome Analysis Network - Breast (SCAN-B) study (ClinicalTrials.gov ID NCT02306096) were included. 109 had chemotherapy (>90% with sequential epirubicin + cyclophosphamide and a taxane, EC–T) according to national guidelines either as NAC (32%) or adjuvant (68%) therapy. Pathogenic BRCA1/2 variants were detected in 11 of 54 cases. Microsatellite instability and BRCA1met using pyrosequencing were investigated in all cases, including analyses of pre-treatment biopsies and surgical resections for NAC patients with residual disease (RD). The NAC patient cohort was extended with six additional SCAN-B patients to further explore treatment response in relation to BRCA1met. Clinicopathological and molecular variables were obtained through clinical review and complementary RNA-seq data.
Results
MSI and BRCA1met was observed in 2% and 17% of patients, respectively. BRCA1met was correlated to younger age and the PAM50 Basal phenotype (92%) and was frequent (40%) in women without pathogenic BRCA1/2 germline variants. No association was observed between BRCA1met and distant recurrence-free interval in adjuvant treated patients (log-rank p=0.77), nor between BRCA1met and pathological response in NAC patients (p=0.69). BRCA1met NAC cases revealed differences in methylation level and BRCA1 mRNA expression in pre-treatment versus surgically resected tissue in patients with RD. No BRCA1 gene fusions were detected. Genetic alterations between pre-treatment vs surgically resected tissue are further analyzed using whole genome sequencing.
Conclusions
BRCA1met is associated with young age in TNBC but hold no predictive nor prognostic value in this patient cohort. We observe a difference in BRCA1met patterns and BRCA1 mRNA expression in NAC patients with RD that may potentially be related to treatment resistance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16